Novartis AG (NVS)
26 Aug 2016
ZURICH, Aug 25 Novartis AG said a late-stage study showed its oral, once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.
ISTANBUL/ZURICH Turkey's investigation into Novartis is "ongoing", a Turkish health ministry official told Reuters on Thursday, after the Swiss drugmaker said last week it was not under investigation over bribery allegations in Turkey.
* Novartis says still sees matter as closed, making checks (Updates to show Novartis no longer seeking information from Turkey)
* Jacobs awarded contract for Novartis Biotechnology Center expansion in France
Canadian drugmaker Valeant Pharmaceuticals International Inc on Monday named a new general counsel and announced the departure of its public relations head.
LONDON AstraZeneca shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.
ZURICH, Aug 3 Novartis AG breast cancer pill LEE011 has won breakthrough therapy designation from U.S. regulators as a first-line treatment for a form of advanced breast cancer, the Swiss drugmaker said on Wednesday.
LONDON GlaxoSmithKline and Google parent Alphabet's life sciences unit are creating a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting a novel field of medicine called bioelectronics.
* Uses miniaturised implants attached to individual nerves (Adds interview with executive, further details)
* Notified by Novartis that FDA has lifted clinical hold on phase 1/2 clinical trial of CGF166 in patients with severe to profound hearing loss Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
|Johnson & Johnson (JNJ.N)||$119.04||+0.47|
|Pfizer Inc. (PFE.N)||$34.82||+0.05|
|Merck & Co., Inc. (MRK.N)||$62.85||+0.53|
|Roche Holding Ltd. (ROG.S)||CHF240.70||-0.20|
|Roche Holding Ltd. (RO.S)||CHF241.00||-1.00|
|Abbott Laboratories (ABT.N)||$42.98||+0.14|
|Sanofi SA (SASY.PA)||€68.90||-0.45|
|AstraZeneca plc (AZN.L)||4,955.00p||-56.00|
|GlaxoSmithKline plc (GSK.L)||1,649.50p||-3.50|
|Eli Lilly and Co (LLY.N)||$78.24||+0.23|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (NVS). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : ValuEngine, Inc.
Provider : Pechala's Reports
Novartis AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
Validea Guru Analysis Report for NVS. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others.
Provider : Validea
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.